Revenue ReboundA large TTM revenue rebound (+222.8% to ~$1.01M) signals renewed demand for BioCorRx’s recovery offerings. Sustained top-line growth provides the foundation to scale clinical programs, absorb fixed costs, and improve unit economics over the next several quarters if the trend continues.

Moderate Gross MarginA ~33.7% gross margin indicates the business retains a material share of revenue to cover operating expenses. That margin level gives room for operating leverage as revenues grow, supporting a plausible pathway to improved operating profitability without requiring immediate, drastic cost restructuring.

Improving Cash Flow TrendFree cash flow improving ~19.5% TTM shows management beginning to reduce cash burn and improve operational efficiency. While still negative, a consistent improvement trend reduces near-term financing pressure and, combined with revenue growth, supports a sustainable path toward positive cash generation.

Bears Say

Negative Stockholders' EquityMaterial negative equity (~-$12.8M) is a structural capital-structure weakness that limits financial flexibility and increases refinancing risk. It can impair the company’s ability to raise capital on favorable terms, negotiate with creditors, and execute growth plans without dilutive or costly financing.

Persistent Cash BurnSustained negative operating cash flow (~-$1.70M TTM) forces ongoing reliance on external financing or asset sales, constraining reinvestment in programs and scaling. Until operating cash flow turns positive, the business remains vulnerable to funding interruptions and higher capital costs.

Severely Negative ProfitabilityExtremely negative net margin (~-400%) and negative EBIT/EBITDA reflect a cost structure far above current revenue levels. Without structural margin improvement or sustained, sizable revenue expansion, profitability is unlikely, limiting free cash flow generation and long-term viability absent continued external support.

BioCorRx News

BioCorRx Enters Securities Purchase Agreement with Investors

BioCorRx ( ($BICX) ) just unveiled an announcement. On July 29, 2025, BioCorRx Inc. entered into a securities...

7M ago

BICX

BioCorRx Inc Board Sees Dual Director Resignations

BioCorRx Inc (BICX) has shared an announcement. Brady Granier and Harsha Murthy have both resigned from their positions...

2y ago

BICX

BICX FAQ

What was BioCorRx Inc’s price range in the past 12 months?

BioCorRx Inc lowest stock price was $0.20 and its highest was $0.50 in the past 12 months.

What is BioCorRx Inc’s market cap?

BioCorRx Inc’s market cap is $7.11M.

When is BioCorRx Inc’s upcoming earnings report date?

BioCorRx Inc’s upcoming earnings report date is Aug 17, 2026 which is in 182 days.

How were BioCorRx Inc’s earnings last quarter?

BioCorRx Inc released its earnings results on Aug 14, 2025. The company reported -$0.07 earnings per share for the quarter, the consensus estimate of -$0.07 by $0.

Is BioCorRx Inc overvalued?

According to Wall Street analysts BioCorRx Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BioCorRx Inc pay dividends?

BioCorRx Inc does not currently pay dividends.

What is BioCorRx Inc’s EPS estimate?

BioCorRx Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BioCorRx Inc have?

BioCorRx Inc has 23,685,343 shares outstanding.

What happened to BioCorRx Inc’s price movement after its last earnings report?

BioCorRx Inc reported an EPS of -$0.07 in its last earnings report, expectations of -$0.07. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of BioCorRx Inc?

Currently, no hedge funds are holding shares in BICX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BioCorRx Inc

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.